Invention Grant
- Patent Title: Anti-BAFF-anti-IL-17 bispecific antibodies
- Patent Title (中): 抗BAFF-抗IL-17双特异性抗体
-
Application No.: US13863544Application Date: 2013-04-16
-
Publication No.: US09359448B2Publication Date: 2016-06-07
- Inventor: Barrett Allan , Robert Jan Benschop , Jirong Lu
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Gregory A. Fox
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C12P21/08 ; A61K39/395 ; A61K39/40 ; C07K16/46 ; C07K16/24 ; C07K16/28 ; C07K1/00
Abstract:
Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).
Public/Granted literature
- US20130280256A1 ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES Public/Granted day:2013-10-24
Information query
